Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017)

Table 5 HIV, HBsAg, anti-HCV, HCV PCR prevalence and HCV viraemic rate among participants (n = 3439)

	SWs (n = 1528)					MSM (n = 746)			PWUD/ID (n = 1165)			TOTAL
	CT	PE	Mthatha	DBN	PMB	CT	JHB	PTA	CT	DBN	PTA
N	384	248	248	399	249	250	250	246	367	398	400	3439
HIV + ve	69 (18%)	90 (38%)	133 (56%)	220 (55%)	199 (80%)	101 (40%)	122 (49%)	97 (41%)	22 (6%)	65 (16%)	140 (35%)	1258 (37%)
HBsAg + ve	13 (3%)	8 (3%)	10 (4%)	17 (4%)	13 (5%)	9 (4%)	10 (4%)	6 (2%)	20 (5%)	15 (4%)	20 (5%)	141 (4%)
Anti-HCV + ve ELISA	1 (< 1%)	0	0	0	0	16 (6%)	3 (1%)	1 (< 1%)	136 (37%)	113 (28%)	288 (72%)	558 (16%)
HCV viral load detectable	0	0	0	0	0	15 (6%)	2 (1%)	0	102 (28%)	90 (23%)	227 (57%)	436 (13%)
HCV viraemic rate (among anti_HCV + ve)	0	0	0	0	0	94%	67%	0	75%	80%	79%	78%
Anti-HCV-HIV co-infection	0	0	0	0	0	6 (2%)	3 (1%)	1 (< 1%)	10 (3%)	25 (6%)	113 (28%)	158 (5%)
Anti-HCV prevalence among HIV + ve participants	0	0	0	0	0	6 (6%)	3 (2%)	1 (1%)	10 (45%)	25 (38%)	113 (81%)	158 (13%)
Anti-HCV-HBV co-infection	0	0	0	0	0	1 (< 1%)	0	0	5 (1%)	5 (1%)	17 (4%)	28 (< 1%)
HIV-HBsAg co-infection	5 (1%)	3 (1%)	9 (4%)	13 (3%)	12 (5%)	5 (2%)	7 (3%)	3 (1%)	3 (1%)	6 (2%)	9 (2%)	75 (2%)
HIV-anti-HCV-HBV co-infection	0	0	0	0	0	0	0	0	0	2 (1%)	8 (2%)	10 (< 1%)

CT Cape Town, DBN Durban, JHB Johannesburg, PE Port Elizabeth, PMB Pietermaritzburg, PTA Pretoria

ISSN: 1471-2334